Business Wire (Fri, 8:30AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
628 people get IPXL articles and Market Currents by email alert.
Get email alerts on IPXL »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
Business Wire (May 10, 2013)
-
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 29, 2013)
-
-
-
Business Wire (Apr 3, 2013)
-
-
Business Wire (Mar 4, 2013)
-
Business Wire (Mar 1, 2013)
-
-
Business Wire (Feb 25, 2013)
-
Business Wire (Feb 8, 2013)
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
5 Biotechs With January FDA Decision Date CatalystsDavid Zanoni • Mon, Dec 17, 2012
-
-
-
-
Using Options To Benefit From The Binary Nature Of FDA DecisionsDavid Anber • Thu, Oct 18, 2012 -
Top Ranked Stocks To Buy This WeekTodd Campbell • Tue, Oct 9, 2012 -
-
-
-
-
-
Impax Laboratories Inc. Q2 2010 Earnings Call TranscriptTue, Aug 3, 2010
-
Impax Laboratories Inc. Q1 2010 Earnings Call TranscriptTue, May 4, 2010
-
Business Wire (May 10, 2013)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 29, 2013)
-
Business Wire (Apr 3, 2013)
-
at MarketWatch.com (Mar 5, 2013)
-
at MarketWatch.com (Mar 5, 2013)
-
at MarketWatch.com (Mar 4, 2013)
-
Business Wire (Mar 4, 2013)
-
Business Wire (Mar 1, 2013)
-
Business Wire (Feb 25, 2013)
-
Business Wire (Feb 8, 2013)
-
Business Wire (Jan 17, 2013)
-
Business Wire (Jan 4, 2013)
-
Business Wire (Jan 2, 2013)
-
Business Wire (Dec 13, 2012)
-
Business Wire (Nov 20, 2012)
IPXL vs. ETF Alternatives
Company Description
Currently, there's no company description for IPXL.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, May 17, 11:23 AM Impax Laboratories (IPXL -1.2%) says its Generic Division, Global Pharmaceuticals, has begun shipping its generic drug Zomig, which is used for the treatment of migraines in adults, as part of a licensing and distribution agreement with AstraZeneca (AZN). Comment! [Healthcare, Global & FX]
- Friday, May 10, 3:36 PM Shares of Endo Health (ENDP -3.6%) trade lower following a brief halt after the FDA denies its petition to block generic versions of its Opana ER. ZGNX +2.1%, IPXL +8.4%. Comment! [Healthcare, On the Move]
- Wednesday, May 1, 4:15 PM Impax Labs (IPXL): Q1 EPS of $0.37 beats by $0.16. Revenue of $148.5M beats by $19.65M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, May 1, 12:10 AM Notable earnings after Wednesday’ s close: ALL, ARI, ARR, ATML, ATO, ATW, AXLL, AXTI, BKD, BMR, CACI, CAR, CBS, CJES, CNQR, CSOD, CVD, CVI, CVRR, CWT, CXO, DVR, DX, DXCM, DXPE, EDMC, ESS, EXPD, EXXI, FB, FNF, FRT, G, GLUU, GNK, GTAT, HNSN, HR, IPI, IPXL, IVR, JDSU, KIM, LNC, LOCK, LVS, MAC, MAR, MET, MUR, NAVB, NGD, NLY, NTRI, PHH, POL, PRU, PSE, PXD, QUIK, ROVI, SAM, SFLY, SGMO, SLTM, SNCR, STX, TEG, TGI, TPC, TSO, TTEK, UAN, UNM, V, VVC, WES, WLT, YELP Comment! [Earnings]
- Tuesday, April 30, 5:35 PM Notable earnings after Wednesday’ s close: ALL, ARI, ARR, ATML, ATO, ATW, AXLL, AXTI, BKD, BMR, CACI, CAR, CBS, CJES, CNQR, CSOD, CVD, CVI, CVRR, CWT, CXO, DVR, DX, DXCM, DXPE, EDMC, ESS, EXPD, EXXI, FB, FNF, FRT, G, GLUU, GNK, GTAT, HNSN, HR, IPI, IPXL, IVR, JDSU, KIM, LNC, LOCK, LVS, MAC, MAR, MET, MUR, NAVB, NGD, NLY, NTRI, PHH, POL, PRU, PSE, PXD, QUIK, ROVI, SAM, SFLY, SGMO, SLTM, SNCR, STX, TEG, TGI, TPC, TSO, TTEK, UAN, UNM, V, VVC, WES, WLT, YELP 2 Comments [Earnings]
- Monday, April 29, 10:30 AM GlaxoSmithKline (GSK +0.1%) breaks off its relationship with Impax Laboratories (IPXL -1.1%) regarding the experimental Parkinson's drug Rytary due to "delays in the anticipated regulatory approval and launch dates in the countries in which GSK has rights to commercialize the product." GSK was working to develop and market Rytary outside of the U.S. and Taiwan. IPXL shares have yet to fully recover from a steep decline in March stemming from FDA concerns about the testing and evaluation process for Rytary. (PR) 1 Comment [Healthcare]
-
Tuesday, March 5, 12:55 PM
Midday top 10 gainers: ACUR +59%. HIMX +37%. MTG +25%. CREE +15%. APP +15%. ZOLT +15%. ASNA +14%. SNTS +14%. PKOH +14%. DYAX +13%.
Midday top 10 losers: IPXL -25%. RNIN -23%. DRWI -19%. REGI -17%. TELOZ -17%. SHIP -14%. CSUN -10%. SDT -10%. JCP -10%. PSTR -9%. Comment! [On the Move] -
Tuesday, March 5, 9:10 AM
Premarket gainers: HIMX +21%. ASNA +13%. ACRX +12%. MTG +11%. SNTS +9%. CREE +6%.
Losers: IPXL -21%. RNIN -16%. Comment! [On the Move] - Monday, March 4, 6:30 PM Impax Laboratories (IPXL) gets hammered after FDA inspectors say they've found continuing problems at the company's Hayward, California manufacturing facility that may affect new and pending drug applications. Issues the agency found include problems related to the testing and evaluation processes for its Parkinson's drug candidate Rytary, as well as other products. Inspectors also said the company failed to identify the cause of broken tablets of its anti-inflammatory drug Carprofen. Shares -18.8% AH. 2 Comments [Healthcare, On the Move]
-
Monday, March 4, 5:39 PM
After-hours top gainers, as of 5:15 p.m.: ASNA +13%. SNTS +8%. CPWR +4%. NDZ +3%. MTG +3%.
After-hours top losers: IPXL -20%. JCP -6%. GMXR -6%. TVL -3%. NSU -3%. Comment! [On the Move] - Monday, February 25, 4:18 PM Impax Labs (IPXL): Q4 EPS of $0.30 beats by $0.11. Revenue of $141.1M (-11% Y/Y) beats by $14.07M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Monday, February 25, 12:10 AM Notable earnings after Monday’s close: ADSK, CZR, HALO, HCN, IPXL, LGCY, MELI, MR, OAS, OKE, OKS, SGY, TWI, URS, VVUS Comment! [Earnings]
- Sunday, February 24, 5:35 PM Notable earnings after Monday’s close: ADSK, CZR, HALO, HCN, IPXL, LGCY, MELI, MR, OAS, OKE, OKS, SGY, TWI, URS, VVUS Comment! [Earnings]
-
Tuesday, January 22, 12:45 PM
Midday top 10 gainers: PBIB +32%. DQ +18%. TECUA +18%. ONP +17%. USEG +17%. RDCM +17%. CIMT +14%. BOX +14%. MTRX +12%. PRCP +12%.
Midday top 10 Losers: CALI -12%. OIBR -12%. BVX -10%. DOM -9%. ARNA -8%. IIVI -8%. AMRI -8%. UPI -8%. IPXL -8%. EXFO -7%. Comment! [On the Move] - Monday, January 14, 2:32 PM Investors interested in the prospects of young biotech companies might want to take a look at this Seeking Alpha article. It's a list of the upcoming FDA approval decision dates for Q1 2013, and with many of these developing firms having a good portion of their businesses riding on FDA approval decisions for their newly developed drugs, the stocks are likely to be sensitive to any positive or negative news over the near term. Comment! [Healthcare, Quick Ideas]
- Tuesday, December 4, 2012, 10:11 AM The patent cliff has been good for generic-drugs companies this year, with over 40 brand-name treatments with $35B of annual sales losing their IP protection. However, the sector faces its own patent cliff over the next couple of years, due to fewer drugs losing that protection. In response, the generic companies are specializing in treatments that are hard to make, selling their own branded medicines, or making big acquisitions. 1 Comment [Healthcare]
-
- View all 0 replies
-
- View all 0 replies
-
Scott Matusow
I will be writing about $LGND and others very soon. some other good one out there like $IPXL and $THRX - View all 3 replies
-
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Justin M. Hall
8/6/11 12A ET: (IPXL, TECH, THRX, EXEL, CEPH) BIOTECH CORRECTION Called in June 2011 => Were You Paying Attention? http://seekingalpha.com/p/4bsg - View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
Scott Matusow
I will be writing about $LGND and others very soon. some other good one out there like $IPXL and $THRX - View all 3 replies
-
-